The Cigna Group provides insurance and related products and services in the United States.
$293.59-2.62%
报价 2026-11-06
市值
$77.58B
EV
$93.64B
PE (TTM)
11.7x
预期 PE (FY2026)
9.6x
52 周区间距高点 -7.1%
$258.08$315.88
筛选结果
pipeline · 2026-11-06Keep✗ 高增长✓ Cheap✗ GARP
Cheap Pool: PE <= 12, EV/EBITDA <= 8, P/FCF <= 12
爆发潜力
2026-11-07未命中✗ 收入线✗ EPS 线
| 财年 | 收入倍数 | EPS | PE |
|---|---|---|---|
| FY+22027-12 | 1.0x | 31.63 → 33.49（1.1x） | 8.8 |
| FY+32028-12 | 1.1x | 31.63 → 37.14（1.2x） | 7.9 |
毛利率 9% · TTM 收入 $286317M · 基数 EPS 31.63（调整后）
电话会信号
辅助标签Q3 20262026-11-05
扩产上调指引
指引 上调
信心 4
分析师 3
“We remain confident in delivering at least 10% adjusted EPS growth in 2027 off of our 2026 run-rate of approximately $30.”
原文引用（2）
- 扩产：we continue to expand our capacity for these limited distribution products with our network of clean rooms, the fifth of which is now in a build phase
- 上调指引：we are raising our full year 2026 adjusted earnings per share outlook to at least $30.60
蓝色标签在暴涨研究中略有区分度；悬停查看口径。
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| CICigna Corporation | $77.58B | -2.6% | +4.5% | 9.5% | 11.7x | 7.8x | 9.2x | Cheap |
| CVSCVS Health Corporation | $107.24B | +3.1% | +1.7% | 13.8% | 51.2x | 17.8x | 13.7x | |
| REGNRegeneron Pharmaceuticals, Inc. | $93.54B | +0.2% | +11.7% | 85.8% | 19.8x | 15.1x | 26.6x | |
| ELVElevance Health Inc. | $91.96B | -1.5% | -1.9% | 25.6% | 11.3x | 9.1x | 29.2x | |
| CORCencora, Inc. | $63.65B | -1.8% | +4.5% | 4.3% | 23.2x | 13.6x | 15.1x | |
| CAHCardinal Health, Inc. | $62.92B | +1.5% | +3.9% | 4.3% | 31.6x | 16.9x | 11.9x | |
| BDXBecton, Dickinson and Company | $57.71B | -0.8% | +2.4% | 45.8% | 25.3x | 14.7x | 17.3x | |
| IDXXIDEXX Laboratories, Inc. | $53.26B | +0.8% | +10.7% | 62.9% | 45.6x | 32.3x | 41.0x | |
| HUMHumana Inc. | $52.08B | +5.3% | +25.8% | 11.7% | 41.8x | 17.8x | 69.7x | |
| 同行中位数 | – | – | +4.2% | 19.7% | 28.5x | 16.0x | 21.9x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。